- AZURE-1 and AZURE-4 to form the basis of Mirum’s U.S. BLA Submission Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) ...
LAS VEGAS, NEVADA -- A California couple says they were fully vaccinated, but still contracted COVID-19 while on vacation as experts say breakthrough cases are possible, especially with the delta ...
Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...
CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results